<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21732">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823964</url>
  </required_header>
  <id_info>
    <org_study_id>AN-EPI3334</org_study_id>
    <nct_id>NCT02823964</nct_id>
  </id_info>
  <brief_title>EASY: Extended Access to Sollpura Over Years</brief_title>
  <official_title>An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and
      amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be
      formulated without enteric coating for administration either as a capsule or as a dosing
      solution dissolved in water or juice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present study is to evaluate the safety of long-term use of liprotamase
      in the management of cystic fibrosis-related exocrine pancreatic insufficiency
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as measured by number of participants with adverse events including clinical or laboratory abnormalities</measure>
    <time_frame>12 months</time_frame>
    <description>Descriptive analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malabsorption scores</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Liprotamase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liprotamase</intervention_name>
    <description>Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement</description>
    <arm_group_label>Liprotamase</arm_group_label>
    <other_name>Sollpura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with cystic fibrosis-related exocrine pancreatic
             insufficiency who received liprotamase and completed Study AN-EPI3331 (SOLUTION:
             Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With
             Cystic Fibrosis)

        Exclusion Criteria:

          -  Any medical, psychological, or social condition that may put the subject at increased
             risk by participating in this study.

          -  Females who are nursing, pregnant, intending to become pregnant, or intending to
             nurse during the time of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Ramza</last_name>
    <phone>510-856-5607</phone>
    <email>nramza@anthera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 114</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 134</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 121</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 501</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 303</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-Bihar</state>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 302</name>
      <address>
        <city>Torokbalint</city>
        <state>Pest County</state>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 304</name>
      <address>
        <city>Mosdos</city>
        <state>Somogy County</state>
        <zip>7257</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 301</name>
      <address>
        <city>Ajka</city>
        <state>Veszprem County</state>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 601</name>
      <address>
        <city>Jerusalem</city>
        <zip>9124001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 203</name>
      <address>
        <city>Karpacz</city>
        <zip>58-540</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 206</name>
      <address>
        <city>Lodz</city>
        <zip>90-329</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 205</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 202</name>
      <address>
        <city>Rabka-Zdroj</city>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 209</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-612</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 401</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 21, 2016</lastchanged_date>
  <firstreceived_date>June 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exocrine pancreatic insufficiency</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>pancreatic enzyme replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
